Elan shares fall as drug fails test

Shares in Elan fell yesterday when, together with US company Biogen, it announced that the Drug Antegren, failed an important clinical trail.

Shares in Elan fell yesterday when, together with US company Biogen, it announced that the Drug Antegren, failed an important clinical trail.

Antegren is an experimental drug for Crohn’s disease, an inflammatory bowel condition affecting around one million people globally.

You have reached your article limit. Already a subscriber? Sign in

Clubber TV and Irish Examiner logos in offer banner

Every Match. Every Story.

One Ultimate Bundle

No obligation. Ts&Cs apply.

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited